Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Other Non Operating Income (2019 - 2026)

Kymera Therapeutics has reported Other Non Operating Income over the past 8 years, most recently at $14.9 million for Q1 2026.

  • Quarterly Other Non Operating Income rose 67.32% to $14.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $44.3 million through Mar 2026, up 18.06% year-over-year, with the annual reading at $38.4 million for FY2025, 1.7% up from the prior year.
  • Other Non Operating Income was $14.9 million for Q1 2026 at Kymera Therapeutics, up from $11.0 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $14.9 million in Q1 2026 and troughed at $290000.0 in Q1 2022.
  • The 5-year median for Other Non Operating Income is $8.1 million (2025), against an average of $6.8 million.
  • Year-over-year, Other Non Operating Income skyrocketed 12650.0% in 2022 and then dropped 9.78% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at $3.8 million in 2022, then surged by 36.52% to $5.1 million in 2023, then skyrocketed by 94.61% to $10.0 million in 2024, then increased by 10.02% to $11.0 million in 2025, then surged by 35.57% to $14.9 million in 2026.
  • Per Business Quant, the three most recent readings for KYMR's Other Non Operating Income are $14.9 million (Q1 2026), $11.0 million (Q4 2025), and $10.3 million (Q3 2025).